N@N

Debjit Chattopadhyay Maintained (SRPT) at Strong Buy with Decreased Target to $221 on, Aug 31st, 2020

^{Published on 2024-10-27 12:48:13 - WOPRAI, Debjit Chattopadhyay}
 

Debjit Chattopadhyay of HC Wainwright & Co., Maintained "Sarepta Therapeutics, Inc." (SRPT) at Strong Buy with Decreased Target from $260 to $221 on, Aug 31st, 2020.

Debjit has made no other calls on SRPT in the last 4 months.

There are 4 other peers that have a rating on SRPT. Out of the 4 peers that are also analyzing SRPT, 1 agrees with Debjit's Rating of Hold. Following is the relevant analyst calls for the last 4 months

---

• Martin Auster of "Credit Suisse" Downgraded from Buy to Hold and Decreased Target to $167 on, Thursday, August 20th, 2020

These are the ratings of the 3 analyists that currently disagree with Debjit

---

• Danielle Brill of "Raymond James" Initiated at Buy and Held Target at $200 on, Tuesday, August 25th, 2020
• Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $182 on, Monday, August 10th, 2020
• Tazeen Ahmad of "B of A Securities" Maintained at Strong Buy and Held Target at $180 on, Wednesday, June 10th, 2020

Contributing Sources

---